Professional Diversity Network (PDN) Hosts Successful Virtual Career Fair for Women’s History Month
25 mars 2024 09h10 HE
|
Professional Diversity Network, Inc.
CHICAGO, March 25, 2024 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ: IPDN) (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
22 mars 2024 10h14 HE
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19 mars 2024 14h20 HE
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23 févr. 2024 13h50 HE
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Subcutaneous Biologics Market Size & Share to Exceed USD 656.3 Billion by 2034, at CAGR of 12.30% - By PMI
08 févr. 2024 16h30 HE
|
PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Subcutaneous Biologics Market size was valued at about USD 205.2 Billion in 2024 and expected to grow at CAGR...
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
10 janv. 2024 15h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
07 déc. 2023 12h01 HE
|
Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
13 nov. 2023 09h22 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
Axial Spondyloarthritis Market Awareness Campaigns Promote Early Diagnosis and Improved Outcomes – By PMI
17 oct. 2023 13h30 HE
|
PMI
Covina, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis affects joints in axial skeleton such as chest, pelvis and spine. Skin and nail changes of Psoriasis, longstanding low back pain,...
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
03 oct. 2023 13h57 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...